Trial Profile
A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vofatamab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIERCE 22
- Sponsors Rainier Therapeutics
- 30 May 2020 This trial has been completed in Poland according to European Clinical Trials Database record.
- 09 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Dec 2019 This trial has been completed in France, according to European Clinical Trials Database.